Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00857)
Name
Aztreonam
Synonyms    Click to Show/Hide the Synonyms of This API
aztreonam; Azactam; 78110-38-0; Primbactam; SQ-26776; SQ-28429; Azthreonam; MFCD00072145; NSC646279; CHEMBL158; SQ 26776; UNII-G2B4VE5GH8; NSC-646279; 2-[[(Z)-[1-(2-Amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methylpropionic Acid; C13H17N5O8S2; G2B4VE5GH8; CHEBI:161680; Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2alpha,3beta(E)))-; Squibb 26776; SR-01000841814; Aztreonam (Azactam, Cayston); Azetreonam; rel-Aztreonam; E-Aztreonam; 99341-02-3; Prestwick_914; PubChem13620; Prestwick2_000185; Prestwick3_000185; BSPBio_000109; [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid; MLS003915628; MLS006011974; Aztreonam, analytical standard; BIDD:GT0765; BPBio1_000121; BCPP000356; HMS1568F11; HMS2090K09; HMS2095F11; HMS3712F11; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid; HY-B0129; BDBM50240480; ZINC12503091; AKOS015840157; AKOS015961777; AC-4330; BCP9000372; CCG-220185; CS-1902; NCGC00179656-01; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid; 2-[(Z)-[1-(2-aminothiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]amino]-2-oxo-ethylidene]amino]oxy-2-methyl-propanoic acid; AS-13760; SMR002204030; SMR004703537; SO 26776; S1505; J10266; 110A380; SR-01000841814-2; SR-01000841814-3; BRD-K62607865-001-03-0; Q27262730; Aztreonam, United States Pharmacopeia (USP) Reference Standard; Aztreonam, Pharmaceutical Secondary Standard; Certified Reference Material; (2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate; (2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate(aztreonam); (Z)-2-[[[(2-Amino-4-thiazolyl)[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3- azetidinyl]carbamoyl]methylene]amino]oxy]-2-methylpropionic acid; 149496-40-2; 2-((((E)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid; 2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid; 2-[1-(2-Amino-thiazol-4-yl)-1-((2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-ylcarbamoyl)-meth-(Z)-ylideneaminooxy]-2-methyl-propionic acid; Propanoic acid, 2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl-
Clinical Status
Approved
PubChem CID
5742832
Formula
C13H17N5O8S2
Canonical SMILES
C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\\OC(C)(C)C(=O)O)/C2=CSC(=N2)N
InChI
1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1
InChIKey
WZPBZJONDBGPKJ-VEHQQRBSSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5742832"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 435.4 Topological Polar Surface Area 238
XlogP 0.3 Complexity 808
Heavy Atom Count 28 Rotatable Bond Count 7
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 12
Full List of Drug Formulations (DFMs) Containing This API
          Aztreonam 75mg/vial for solution Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lysine; Sodium Chloride
                   Dosage Form For Solution
                   Company Gilead
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Aminutrin DIG Info Glutathione reductase (Ki = 54600 nM) [1]
          Aztreonam 500mg/vial injectable Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Arginine
                   Dosage Form Injectable
                   Company Bristol Myers Squibb
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Arginine DIG Info GPCR33 receptor (EC50 = 284000 nM) [2]
References
1 Design, synthesis and biological evaluation of novel nitroaromatic compounds as potent glutathione reductase inhibitors. Bioorg Med Chem Lett. 2011 Sep 15; 21(18):5398-402.
2 A highly selective agonist for the metabotropic glutamate receptor mGluR2. Med Chem Comm. (2011) 2:1120-1124.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.